"We are pleased to re-engage with the research
Post# of 30028
Posted On: 08/29/2014 7:12:34 AM
"We are pleased to re-engage with the research community regarding our PhenoGuard discovery platform, now that MANF has achieved proof of concept across a number of therapeutic indications, and is on a path for first-in-man studies in retinal disorders and Parkinson's disease," said Gerald C. Commissiong, President & CEO of Amarantus. "We believe the discovery of a second family of neurotrophic factors would represent a sea-change in the research community and further validate the uniqueness and value of our technology."
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼